What multi-omics strategies are being studied for psoriatic arthritis?
Researchers are using multi-omics strategies to better understand psoriatic arthritis (PsA). Multi-omics means studying many layers of biological information at once, such as genes (genomics), RNA (transcriptomics), proteins (proteomics), and gut bacteria (microbiomics). The goal is to improve early diagnosis, predict which treatments will work best for each person, and find new targets for therapy. A 2025 narrative review summarizes these efforts and highlights their potential for precision medicine in PsA 1.
What the research says
A 2025 narrative review systematically looked at multi-omics studies in PsA and related conditions called spondyloarthritis 1. The review found that single-omics approaches (looking at only one type of data) give a limited picture of the disease. By combining genomics, transcriptomics, proteomics, and microbiomics, researchers can uncover shared and unique disease mechanisms, help tell PsA apart from other forms of arthritis, and discover new biomarkers (biological signs of disease) 1.
The review emphasizes that integrated multi-omics can help with early diagnosis, monitoring disease activity, predicting how a patient will respond to treatment, and identifying new therapeutic targets 1. For example, combining genetic risk factors with protein and microbiome data might reveal why some patients respond well to certain biologic drugs while others do not. This could lead to more personalized treatment plans.
Other studies on PsA treatments, such as those on secukinumab and ustekinumab, focus on single drugs rather than multi-omics 67. However, the multi-omics framework aims to predict which patients will benefit from these therapies before they start. The review also notes that multi-omics could refine how we classify PsA subtypes, moving beyond symptoms to molecular profiles 1.
What to ask your doctor
- Could multi-omics testing (like genetic or protein profiling) help guide my treatment choices for psoriatic arthritis?
- Are there any ongoing studies or clinical trials using multi-omics to predict how well I might respond to a specific biologic?
- How might combining information from my genes, blood proteins, and gut microbiome improve my care?
- Is there a role for multi-omics in monitoring my disease activity or detecting early signs of joint damage?
- What are the current limitations of multi-omics approaches, and when might they become part of routine care?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.